CGRP-targeted migraine therapies for vascular risk patients

Migraine is one of the most common neurological disorders and affects millions of people worldwide. With the development of CGRP-targeted therapies – monoclonal antibodies and Gepanten – the treatment of this widespread disease has experienced a turning point in recent years. These substances are highly effective, have a favorable side-effect profile and are clearly pathophysiologically targeted. However, one patient group remains cautious: people with vascular risk factors or who have already suffered cerebrovascular disease. Particularly in this group, which was often excluded from clinical trials, crucial questions arise: How safe is blockade of the CGRP system really? What data is available and where are there still gaps?